Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study-Reference-Cited by-同舟云学术

Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study

Published:2015-05-23 Issue:11 Volume:141 Page:2047-2060
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Hochhaus Andreas,Baccarani Michele,Giles Francis J.,le Coutre Philipp D.,Müller Martin C.,Reiter Andreas,Santanastasio Helene,Leung Mimi,Novick Steven,Kantarjian Hagop M.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/article/10.1007/s00432-015-1988-0/fulltext.html

Reference63 articles.

1. Akin C, Metcalfe DD (2004) The biology of Kit in disease and the application of pharmacogenetics. J Allergy Clin Immunol 114:13–19

2. Andersen CL, Kristensen TK, Severinsen MT et al (2012) Systemic mastocytosis—a systematic review. Dan Med J 59:A4397

3. Buet D, Gallais I, Lauret E et al (2012) Cotargeting signaling pathways driving survival and cell cycle circumvents resistance to kit inhibitors in leukemia. Blood 119:4228–4241

4. Casassus P, Caillat-Vigneron N, Martin A et al (2002) Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol 119:1090–1097

5. Erben P, Schwaab J, Metzgeroth G et al (2014) The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. Ann Hematol 93:81–88

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Detecting Changes in Mast Cell Numbers Versus Activation in Human Disease: A Roadblock for Current Biomarkers?;The Journal of Allergy and Clinical Immunology: In Practice;2024-07

2. Unraveling the Rare Entity of KIT D816V-Negative Systemic Mastocytosis;Journal of Hematology;2024-06

3. c-Kit Receptors as a Therapeutic Target in Cancer: Current Insights;OncoTargets and Therapy;2023-09

4. Acute mast cell leukemia without KIT D816V mutation and lack of CD2 and CD25—a case report of rare entity;Journal of Hematopathology;2023-01-20

5. Avapritinib for the treatment of KIT mutation–negative systemic mastocytosis;Baylor University Medical Center Proceedings;2022-09-20